MapLight Therapeutics向美国证券交易委员会（SEC）提交了一份招股说明书。该文件显示，公司计划允许售股股东转售最多达13,181,055股普通股。这一举措标志着公司在股权流通方面迈出了重要一步。此次转售安排由相关售股股东主导，MapLight Therapeutics本身并未在此次交易中发行新股。招股说明书的提交，为现有股东提供了在公开市场上出售所持股份的途径。这一动作也反映了公司对市场流动性的关注，以及对股东权益的重视。投资者将密切关注这一潜在股票供应对市场供需平衡的影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.